 VBI Vaccines Inc NASDAQ: VBIV has announced positive Phase 1 data from its Phase 12 trial evaluating its enveloped virus-like particle eVLP COVID-19 vaccine candidate VBI-2902a. VBI-2902a was well-tolerated, with no safety signals observed. 